Elevance Health said its officers expect to reaffirm full-year 2025 shareholders' earnings guidance of approximately $24.10 per diluted share, including approximately $5.90 per diluted share of net unfavorable items.

1. 01

   Elevance Health said its officers expect to reaffirm full-year 2025 shareholders' earnings guidance of approximately $24.10 per diluted share, including approximately $5.90 per diluted share of net unfavorable items.

2. 02

   The company said it continues to expect adjusted shareholders' earnings excluding these items to be approximately $30.00 per diluted share. It added that this guidance does not include any other adjustment items beyond those reported in the company's Q2 2025 earnings.

3. 03

   Elevance Health said its officers are also expected to reaffirm full-year 2025 benefit expense ratio guidance of approximately 90.0%.

4. 04

   The company said these expectations reflect management's current view of market conditions, operational performance, the regulatory and policy landscape, and refinement of key business assumptions, including cost trends and medical claims payable estimates. It added that if business factors or assumptions change, the company's actual results could materially differ from management's current guidance.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.